A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight/Obesity
Latest Information Update: 08 Apr 2026
At a glance
- Drugs Insulin receptor modulators (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 08 Apr 2026 New trial record